Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19

Infection with SARS-CoV-2 is causing a deadly and pandemic disease called coronavirus disease–19 (COVID-19). While SARS-CoV-2–triggered hyperinflammatory tissue-damaging and immunothrombotic responses are thought to be major causes of respiratory failure and death, how they relate to lung immunopathological changes remains unclear. Neutrophil extracellular traps (NETs) can contribute to inflammation-associated lung damage, thrombosis, and fibrosis. However, whether NETs infiltrate particular compartments in severe COVID-19 lungs remains to be clarified. Here we analyzed postmortem lung specimens from four patients who succumbed to COVID-19 and four patients who died from a COVID-19–unrelated cause. We report the presence of NETs in the lungs of each COVID-19 patient. NETs were found in the airway compartment and neutrophil-rich inflammatory areas of the interstitium, while NET-prone primed neutrophils were present in arteriolar microthrombi. Our results support the hypothesis that NETs may represent drivers of severe pulmonary complications of COVID-19 and suggest that NET-targeting approaches could be considered for the treatment of uncontrolled tissue-damaging and thrombotic responses in COVID-19.

Introduction
The COVID-19 pandemic emerged in Wuhan, China, and rapidly spread globally, leading to an overwhelming pressure on healthcare systems that required substantial hygienic and containment measures. Severe acute respiratory coronavirus-2 (SARS-CoV-2) has been identified as the etiological agent of COVID-19 (Wu et al., 2020; Bao et al., 2020), whose clinical manifestations range from the absence of symptoms to an acute respiratory distress syndrome (ARDS) and sometimes multi-organ failure, leading to death (Huang et al., 2020; Chen et al., 2020; Guan et al., 2020). While the determinants of disease severity are not completely understood yet, host factors such as age or an excessive inflammatory response to SARS-CoV-2 have been incriminated (Zhang et al., 2020).

The lungs are main targets of COVID-19, and patients with severe forms of the disease are often admitted to the hospital because of ARDS-associated hypoxemia, a consequence of impaired lung ventilation, diffusion, or perfusion (Huang et al., 2020; Chen et al., 2020; Guan et al., 2020). In addition, thrombotic complications have frequently been associated with COVID-19 in critically ill patients, representing a cause of organ failure and death (Zhou et al., 2020; Connors and Levy, 2020; Ackermann et al., 2020; Terpos et al., 2020; Wichmann et al., 2020; Helms et al., 2020). Since no effective therapeutic options exist for COVID-19, a better understanding of the pathophysiological mechanisms involved in the most severe forms of the disease is a pressing medical need (Bikdeli et al., 2020). In this regard, relationships between fatal forms of COVID-19 and lung immunopathological changes remain to be discovered in order to help the clinical management of the disease.

Neutrophils represent the most abundant leukocyte population in the blood. Of note, neutrophilia and elevated serum levels
of the main neutrophil chemoattractant IL-8 were found in severe cases of COVID-19 and were associated with poor disease outcome (Li et al., 2020; Wang et al., 2020; Zhang et al., 2020). In addition, neutrophils have been shown to infiltrate lungs of hospitalized COVID-19 patients (Barnes et al., 2020; Chen et al., 2020). A powerful feature of activated neutrophils is their ability to form neutrophil extracellular traps (NETs), web-like structures rich in host DNA and containing modified histone proteins and granule proteins such as neutrophil elastase (NE) and myeloperoxidase (MPO; Papayannopoulos, 2018). Initially discovered for their role in bacterial killing (Brinkmann et al., 2004), NETs are now thought to contribute to the pathophysiology of a wide range of infectious or noninfectious diseases (Papayannopoulos, 2018; Jorch and Kubes, 2017). Interestingly, NETs can be formed in the lungs upon infection with respiratory viruses (Schönrich and Raftery, 2016; Radermecker et al., 2019; Toussaint et al., 2017; Narasaraju et al., 2011; Moorthy et al., 2016b; Ashar et al., 2018). Moreover, they have the ability to promote lung damage (Caudrillier et al., 2012; Lefrançais et al., 2018; Narasaraju et al., 2011; Twaddell et al., 2019; Porto and Stein, 2016; Barnes et al., 2020), thrombosis (Ali et al., 2019; Meng et al., 2017; Barnes et al., 2020), and fibrosis (Chrysanthopoulou et al., 2014; Savchenko et al., 2014), three features encountered in severe forms of COVID-19 patients (Ackermann et al., 2020; Wang et al., 2020; Guan et al., 2020; Zhou et al., 2020; Connors and Levy, 2020). Accordingly, NETs have recently been proposed to represent potential drivers of COVID-19, as suggested by several opinion articles (Barnes et al., 2020; Mozzini and Girelli, 2020; Yaqinuddin and Kashir, 2020). Notably, we were not able to find any DAPI+MPO+Cit-H3+ NETs, in lung sections from COVID-19 patients (Fig. 1, A–D). We measured NE/DNA or MPO/DNA complexes are often used to detect DAPI+MPO+Cit-H3+ NETs (Boeltz et al., 2019). The presence of NETs in COVID-19-injured lungs, while they were not detected in lungs from patients who died from another cause. Interestingly, we found that NETs were mainly associated with the inflammatory interstitial lesions and the airways, while NET-prone primed neutrophils were found in pulmonary microcirculation. Our study supports the hypothesis that NETs may contribute to lung pathology in severe COVID-19 and represent putative therapeutic targets.

Results and discussion

Clinical presentation of COVID-19 patients

Postmortem lung samples were collected from four patients who died from COVID-19 at the University Hospital of Liege, Belgium (Table 1). The age ranged from 51 to 73 yr, and one patient was female. Each case tested positive for SARS-CoV-2 by nasopharyngeal swab and RT-PCR at the time of admission. The total duration of the hospitalization until death ranged between 8 and 32 d. Assisted mechanical ventilation was implemented at the time of admission for three patients, and at day 3 after admission for one patient (Table 1). Existing comorbidities and chronic treatments are reported in Table 1. Every patient received in-hospital antiviral (i.e., hydroxychloroquine) and antibiotic therapy. In the last 24 h preceding death, each patient exhibited blood neutrophilia and elevated serum C-reactive protein levels (Table 1). Serum IL-6 levels were elevated in the three patients who were assessed for IL-6, and levels of the fibrin degradation products D-dimers were also above the normal range for the four patients, indicative of ongoing thrombosis and subsequent fibrinolysis (Table 1). Lymphopenia and thrombocytopenia were observed in three out of four patients (Table 1). The identified causes of death were pneumonia, ARDS, or multi-organ failure. Typical lesions of diffuse alveolar damage (Xu et al., 2020) were confirmed by histopathological examination of lung sections by experienced pathologists (Table 1). Hence, the four patients represented prototypical severe and fatal cases of COVID-19, characterized by pneumonia and fatal respiratory distress associated with signs of systemic inflammation, neutrophilia, and coagulopathy (Huang et al., 2020; Chen et al., 2020; Guan et al., 2020; Li et al., 2020; Wang et al., 2020; Tang et al., 2020; Giusti et al., 2020).

NETs are uniquely detected in lung specimens from COVID-19 patients

First, we sought to determine whether NETs could be detected in the lungs of these COVID-19 patients. NETs are released by neutrophils and are defined as extracellular structures containing large amounts of DNA, modified histone proteins such as citrullinated histone H3 (Cit-H3), and granule proteins, including MPO and NE, which both regulate NET formation (Papayannopoulos, 2018; Boeltz et al., 2019). Many methods are being used to detect and quantify NETs (Boeltz et al., 2019). The detection of one single NET component (e.g., cell-free DNA, MPO, NE, Cit-H3) is nonspecific and should therefore be combined with more specific methods. In this regard, assays measuring NE/DNA or MPO/DNA complexes are often used to quantify NET fragments in body fluids or secretions, including the bronchoalveolar lavage fluid (Caudrillier et al., 2012; Bendib et al., 2019; Mikacenic et al., 2018). Nevertheless, immunohistochemistry in tissue section is the most widely used and recommended method, as it allows the unambiguous visualization of extracellular structures containing extracellular DNA and colocalizing with granule-derived proteins and modified histones (Boeltz et al., 2019; Caudrillier et al., 2012; Radermecker et al., 2019; Rocks et al., 2019). We performed immunofluorescence staining on paraffin-embedded lung sections from COVID-19 patients with anti-MPO and anti–Cit-H3 antibodies together with DAPI. Incubation with rabbit and goat sera and secondary antibodies was used as controls (Fig. 1, A–D). We found that NETs, defined as extracellular areas triple positive for DNA-bound DAPI, MPO, and Cit-H3 (i.e., DAPI·MPO·Cit-H3·NETs), in lung sections from COVID-19 patients (Fig. 1, A–H; large arrowheads). We also analyzed lung sections from four “control” patients who died from a COVID-19-unrelated cardiac cause (Table S1). Notably, we were not able to find any DAPI·MPO·Cit-H3·
NETs in lung sections from those non–COVID-19 patients (Fig. 1, A–D; and Fig. S1). Instead, we only sporadically detected MPO+ neutrophils whose nuclei stained positive for Cit-H3 (Fig. 1, A–D; thin arrow). We quantified the volume of extracellular structures displaying a colocalization between MPO and Cit-H3, i.e., MPO+Cit-H3+ NETs, in multiple fields from each patient and confirmed that NETs were uniquely found in COVID-19 lungs, but not in non–COVID-19 control lungs (Fig. 1 I). The absence of NETs in postmortem lung specimens from non–COVID-19 patients rules out the possibility that NETs are formed postmortem, merely as a consequence of death. In addition, in order to address whether the formation of NETs was specific to the lung tissue in COVID-19 patients, we performed similar staining on sections from the liver, pancreas, kidney, and heart from COVID-19 patients for Table 1.

### Table 1. Demographic and clinical characteristics, and hematological and clinical biochemistry findings of COVID-19 patients

| Patient no. | 1 | 2 | 3 | 4 |
|-------------|---|---|---|---|
| Gender      | M | F | M | M |
| Age (yr)    | 56 | 63 | 51 | 73 |
| Known comorbidities | Emphysema, extrinsic asthma | Type 2 diabetes, obesity, hyperanxiety, epilepsy | Type 2 diabetes, hypertension, fatty liver | None |
| Chronic treatments | Inhaled CS and β2 agonists, leukotriene receptor antagonists, SSRI | Anti-diabetes (metformin), neuroleptic (haloperidol), anxiolytic (prothipendyl), anti-epileptic (sodium valproate), L-thyroxin, anti-convulsive (procyclidin) | Anti-diabetes (metformin, empagliflozine), anti-hypertensive (ACE inhibitor, angiotensin 2 receptor antagonist), α1 receptor antagonists | L-thyroxin, aspirin |
| Time from admission to death (d) | 18 | 8 | 32 | 22 |
| Symptom duration before admission (d) | 8 | 7 | 7 | 2 |
| Duration of ventilator management (d) | 15 | 8 | 32 | 22 |
| Secondary lung infection | No | No | Yes | Yes |
| Secondary disorder | Renal failure | Pneumothorax | Renal failure, hypercortisolemia | Renal failure, atrial fibrillation |
| In-hospital antiviral therapy | Yes | Yes | Yes | Yes |
| In-hospital antibiotic therapy | Yes | Yes | Yes | Yes |
| In-hospital antifungal therapy | No | No | Yes | No |
| In-hospital anticoagulant therapy (heparin) | Yes | No | No | No |
| Cause of death | ARDS, multi-organ failure | Pneumonia | ARDS | ARDS |
| Diffuse alveolar damage | Yes | Yes | Yes | Yes |
| Lymphocytes [1.1–4.5 10^3/μl] | 1.41 | 0.17^a | 0.97^a | Below detection^a |
| Neutrophils [1.5–4.5 10^3/μl] | 25.84^b | 8.7^b | 6.93^b | 18.35^b |
| Monocytes [0.1–0.9 10^3/μl] | 1.61^b | 0.34 | 0.75 | Below detection^a |
| Platelets [150–370 10^3/μl] | 217 | 20.4 | 70^a | 26^a |
| CRP [0–5 µg/ml] | 391.4^b | 286.8^b | 183.3^b | 231^b |
| Fibrinogen [1.79–3.86 mg/ml] | 4.43^b | 7.55^b | 3.47 | 5.70^b |
| IL-6 [< 1 IU/ml] | Not measured | 384.8^b | 129.3^b | 1,077.3^b |
| D-dimer [< 500 µg/liter] | 2,106^b | 7,440^b | 9,149^b | 4,559^b |

For hematological and clinical biochemistry values, references ranges are indicated in brackets. ACE, angiotensin-converting enzyme; CRP, C-reactive protein; CS, corticosteroids; F, female; M, male; SSRI, selective serotonin reuptake inhibitor.
^aValues below the reference range.
^bValues above the reference range.

NETs in lung sections from those non–COVID-19 patients (Fig. 1, A–D; and Fig. S1). Instead, we only sporadically detected MPO+ neutrophils whose nuclei stained positive for Cit-H3 (Fig. 1, A–D; thin arrow). We quantified the volume of extracellular structures displaying a colocalization between MPO and Cit-H3, i.e., MPO+Cit-H3+ NETs, in multiple fields from each patient and confirmed that NETs were uniquely found in COVID-19 lungs, but not in non–COVID-19 control lungs (Fig. 1 I). The absence of NETs in postmortem lung specimens from non–COVID-19 patients rules out the possibility that NETs are formed postmortem, merely as a consequence of death. In addition, in order to address whether the formation of NETs was specific to the lung tissue in COVID-19 patients, we performed similar staining on sections from the liver, pancreas, kidney, and heart from COVID-19 patients for
which such material was available. Of note, we did not find any evidence of NET formation in those organs (Fig. S2), suggesting that the systemic presence of NET components reported in sera from COVID-19 patients (Zuo et al., 2020; Middleton et al., 2020) is not associated with widespread NET formation in peripheral organs.

**NETs are distributed in the airway, interstitial, and vascular compartments of COVID-19 lungs**

To gain further insights into the relative abundance of NETs in the lungs of COVID-19 patients, we scanned the entire immunofluorescently stained lung sections and marked the zones that were rich in MPO+Cit-H3+ NETs. This analysis revealed the presence of multiple, widely distributed NET-infiltrating areas in the lungs of COVID-19 patients (Fig. 2, A and B), as depicted by black circles on consecutive H&E-stained sections (Fig. 2 C).

NETs may contribute to different aspects of COVID-19 physiopathology by infiltrating distinct lung compartments. To determine whether NETs were located in particular micro-anatomical localizations and lesions, we performed a detailed histopathological analysis of the NET-infiltrating areas for each patient (Table 2).

First, NETs were largely associated with the airway compartment in the four patients (Table 2 and Fig. 3, A and B). Of note, they were often associated with fibrin, and occluded some alveoli or bronchioles almost completely. Extravascular fibrin deposition could result in leakage of plasma proteins, fibrinogen, and thrombi into the airway lumen (Wagers et al., 2004). Therefore, the presence of NETs in the airway compartment may represent major procoagulant triggers, leading to fibrin deposition and subsequent impaired pulmonary ventilation. In advanced stages, NETs could be replaced by collagen networks, thereby contributing to COVID-19–triggered lung fibrosis (Chrysanthopoulou et al., 2014; Savchenko et al., 2014).

They may also facilitate secondary infections, such as seen in cystic fibrosis (Porto and Stein, 2016; Barnes et al., 2020). In our study, two out of four patients developed a secondary lung infection during hospitalization (Table 1). Even though NETs may also be induced by bacterial-derived mediators during a secondary infection (Porto and Stein, 2016; Hamaguchi et al., 2012; Moorothy et al., 2016a), we found a massive presence of NETs in each patient, regardless of the status of secondary infection. It is thus unlikely that the secondary infection on its own would be solely responsible for the massive and multifocal infiltration of NETs in our study.

Second, the interstitial compartment also contained NETs in three patients, especially in zones infiltrated by neutrophils and macrophages, while no lymphocytes were observed (Table 2 and Fig. 3 C). The proximity between NET-releasing neutrophils and macrophages is consistent with the hypothesis that NET could contribute to the cytokine storm in COVID-19 (Barnes et al., 2020), by triggering IL-1β secretion from macrophages, which would in turn increase NET formation and IL-6 secretion, as reported in other settings (Kahlenberg et al., 2013; Warnatsch et al., 2015; Meher et al., 2018; Sil et al., 2017).

Third, NET-rich zones encompassed the vascular compartment in lungs from three patients, where they mainly localized in arterioles containing microthrombi (Table 2 and Fig. 3 D). It is important to note that, in microthrombi, we mainly observed numerous Cit-H3+MPO+ neutrophils, as reported by others (Middleton et al., 2020), rather than filamentous NETs, supporting that such activated neutrophils are in earlier stages of NET formation. Whether NETs actually contribute to the formation of COVID-19–associated pulmonary microthrombi (Ackermann et al., 2020) merits further investigation. Under conditions of infection-induced lung inflammation, NETs may indeed represent a mechanism by which neutrophils participate in thrombus formation (Laridan et al., 2019; Middleton et al., 2020). NETs form a scaffold for adhesion of platelets (Laridan et al., 2019), adhesion molecules such as von Willebrand factor and fibrinogen, and red blood cells. They mediate histone-induced platelet activation and aggregation. NET components, e.g., histones, DNA, NE, and cathepsin G, also have the ability to activate tissue-factor or factor 12–dependent coagulation, which results in fibrin generation and the formation of platelet- and fibrin-rich thrombi.

**General discussion and conclusions**

Our study reports that NETs infiltrate distinct compartments and lesions in the lungs of COVID-19 patients with a fatal outcome. It was performed on a small number of patients from the same country and hospital, which is an obvious limitation. In addition, our study does not demonstrate the causality between NETs and COVID-19 pathophysiology, as this would only be revealed in large clinical studies or model systems in which NETs would be targeted. These two points highlight the need for additional studies before drawing definitive conclusions about the implication of NETs in COVID-19 physiopathology.

The assisted mechanical ventilation of the patients represents a potential confounding factor for establishing a direct link between COVID-19 and NETs. Indeed, mechanical ventilation can be injurious to the lungs and has been shown to induce NETs (Yildiz et al., 2015; Porto and Stein, 2016). Yet it is mainly triggering alveolar damage, and would arguably induce NETs in the airway compartment only, but not in the interstitial or vascular compartments. Furthermore, a recent study indicates no relationship between ventilation duration and the amount of NETs in the bronchoalveolar lavage fluid from patients with pneumonia–related ARDS (Bendib et al., 2019). Thus, while we cannot rule out a contribution of the assisted mechanical ventilation to the formation of NETs in COVID-19 patients, it is unlikely that this could explain the widespread distribution of NETs in the lungs of COVID-19 patients.

In-hospital antiviral therapy was administered to each COVID-19 patient (Table 1), which may also influence the production of NETs. Nevertheless, data from the literature indicate that chloroquine exhibits an inhibitory effect on NET formation in other contexts (Boone et al., 2018; Moorothy et al., 2019). In addition, we would have expected to see NETs in other organs than the lung if hydroxychloroquine was sufficient to trigger NETs, which was not the case. Further investigations would, however, be necessary to formally exclude an effect of hydroxychloroquine on NETs in COVID-19 lungs.

There is currently no therapy against COVID-19, and several clinical trials are ongoing. Our findings that NETs widely...
infiltrate the lungs of deceased patients can be of major importance. On the one hand, thrombotic events have been suspected to contribute to COVID-19 morbidity and mortality, and current interim guidelines recommend the use of heparin regimens for thromboprophylaxis and anticoagulation treatment (Spyropoulos et al., 2020; Bikdeli et al., 2020). Targeting NETs may represent another potential antithrombotic approach that might prove to be beneficial against both immunothrombosis and venous thromboembolism (Barnes et al., 2020; Middleton et al., 2020). In a clinical study of patients with acute coronary syndrome, DNase, an enzyme that breaks down NETs, has been shown to accelerate lysis of coronary thrombi (Mangold et al., 2015). It is also interesting to note that the prothrombotic effect of NETs could be diminished by heparin (Grässle et al., 2014), providing further support of current recommendations. On the other hand, dysregulated NET formation could aggravate lung damage and the impairment of gas exchanges (Caudrillier et al., 2012; Lefrançais et al., 2018; Narasaraju et al., 2011; Twaddell et al., 2019; Porto and Stein, 2016; Barnes et al., 2020). Inhalation of human recombinant DNase I (pulmozyme/dornase α) has been shown to improve lung function and to reduce secondary infections in cystic fibrosis.
(Fuchs et al., 1994; Konstan et al., 2011), and may be beneficial in the context of COVID-19. In this regard, the Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alfa Administration in Patients with COVID-19-Induced ARDS (COVID-Dornase) clinical trial is currently investigating the potential benefit of aerosolized dornase α administration in hospitalized COVID-19 patients suffering from ARDS (Desilles et al., 2020).

Altogether, our study supports the idea that targeting NETs in COVID-19 patients may help the clinical management of severe forms of COVID-19 by alleviating thrombotic events, excessive tissue-damaging inflammation, fibrosis, and airway obstruction.

**Figure 2.** NETs are broadly distributed in postmortem lung specimens from COVID-19 patients. (A) Photographs of entire antibody-stained immunofluorescence lung sections from COVID-19 patients. (B) Magnification of NET-rich zones, indicated by white boxes in A. MPO+Cit-H3+ NETs are indicated by large arrowheads. (C) Photographs of entire H&E-stained lung sections from COVID-19 patients. NET-infiltrating areas are circled in black. Scale bars, 1 mm (A and C); 100 µm (B).
Materials and methods

Ethics approval

The use of human specimens was approved in 2020 by the Ethics Reviewing Board of the University Hospital of Liege, Belgium (ref. 2020/119).

Human biopsies

We analyzed lung postmortem biopsy specimens from four patients who died from SARS-CoV-2 infection at the University Hospital of Liege (Belgium) and from four patients who died at the same hospital from a COVID-19-unrelated cause. The non–COVID-19 lung controls were archived tissues that were chosen for the best possible match with respect to age and sex. The characteristics of the patients are presented in Table 1 and Table S1. We also analyzed postmortem biopsy specimens isolated from the liver, heart, kidney, and pancreas from two COVID-19 patients for which such material was available. All tissues were provided by the Biobank of the Liege University Hospital and selected by two pathologists after H&E staining.

Hematology and biochemistry of COVID-19 patients

Hematology and blood biochemistry of COVID-19 patients were retrospectively analyzed. We used the last available blood sample taken in the 24 h preceding the patient’s death. All biomarkers have been analyzed by the central laboratory (Hematology and Biochemistry) of the Liege University Hospital.

Histopathological characterization of lungs from COVID-19 patients

The samples were formalin-fixed paraffin-embedded (FFPE), and serial tissue sections of 4 µm were cut for histological and immunofluorescence examination. H&E-stained whole slides were digitized by using a Pannoramic 250 Flash III Scanner (3DHISTECH Ltd.). High-resolution images focused on immunofluorescence-detected NET areas were then assessed by two experienced pathologists by using a scoring system of lesions typically found in SARS-CoV-2 diffuse alveolar damage (Xu et al., 2020) and present in the different lung tissue compartments (alveolar, bronchial, interstitial, and vascular; Table 2).

Immunofluorescence staining and analysis

To identify NETs from lung tissues, lung tissues were FFPE, and lung sections were cut (4-µm-thick sections) for immunofluorescence staining. After deparaffinization and rehydration, tissue sections were boiled for 20 min in 10-mM sodium carbonate buffer for antigen retrieval. Lung sections were permeabilized in PBS 0.5% Triton X-100.

Table 2. Lung histopathological analysis of NET-infiltrating area in COVID-19 patients

| Patient no. | 1 | 2 | 3 | 4 |
|-------------|---|---|---|---|
| No. of NET-infiltrating area identified | Total | 17 | 13 | 14 | 10 |
| | Vascular compartment | 6 | 1 | 1 | 0 |
| | Interstitial compartment | 2 | 0 | 2 | 7 |
| | Alveolar compartment | 9 | 13 | 5 | 5 |
| | Bronchial compartment | 0 | 0 | 8 | 0 |
| Alveolar lesions | Inflammation | PMN, macrophages, fibrin, giant and atypical cells | PMN, macrophages, fibrin, giant and atypical cells | PMN, macrophages, fibrin, rare atypical cells | PMN, macrophages, fibrin, hyaline membranes |
| | Hemorrhage | + | − | + | − |
| Bronchial lesions | Inflammation | / | / | Intra- and peri-bronchial: PMN, macrophages; rare red blood cells and desquamative epithelial cells |
| Interstitial lesions | Inflammation | PMN, macrophages, fibrin, giant cell, atypical cells | / | PMN, macrophages, fibrin | PMN, fibrin |
| | Hemorrhage | + | / | + | − |
| | Fibrosis | + | / | + | + |
| Vascular lesions | Thrombi | + | + | + | / |
| | Affected vessels | Arterioles | Arterioles | Arterioles | / |
| | Other | PMN, fibrin, red blood cells | Fibrin | Fibrin, PMN | / |

Some NET-infiltrating areas encompassed several compartments. /, not applicable (no NET detected in the indicated compartment); −, absent; +, present; PMN, polymorphonuclear leukocytes.
Samples were incubated with a blocking buffer (PBS with 2% BSA and 2% of donkey serum; Sigma-Aldrich) for 1 h at room temperature and stained in blocking buffer with rabbit anti-human antibodies directed against citrullinated histone H3 (Abcam, Ab5103; 1:100 in blocking buffer) and with goat anti-human antibodies directed against MPO (R&D Systems, AF3667; 1:40 in blocking buffer) for 1 h at room temperature. After washing samples with PBS, secondary donkey anti-rabbit IgG antibodies conjugated with Alexa Fluor 568 (1:200 in blocking buffer) and donkey anti-goat IgG antibodies conjugated with Alexa

Figure 3. NETs are found in lesional areas of the lung airway, interstitial, and vascular compartments. (A–D) Representative pictures of H&E staining from lung sections are shown on the left, and representative pictures of immunofluorescence staining from adjacent lung sections are shown on the right (MPO [red] and Cit-H3 [red] merged with DAPI [blue]). The black box on the left indicates the zone shown by immunofluorescence on the right. MPO+Cit-H3+ NETs are indicated by arrowheads. Examples of NETs found (A) in a terminal bronchiole and alveoli, (B) in small bronchi, (C) in the interstitial compartment, and (D) in a microthrombus within an arteriole are shown. Scale bars, 50 µm.
Fluor 488 (1:200 in blocking buffer) were added in blocking buffer containing DAPI (1:1,000) and incubated for 2 h in the dark at room temperature. Finally, samples were mounted with 10 µl of ProLong Antifade reagent (Thermo Fisher Scientific) on glass slides and stored at room temperature in the dark overnight.

All samples were analyzed by fluorescence microscopy using standard filter sets. Controls were stained with secondary antibodies after incubation with sera from host species (i.e., rabbit and goat sera, 2% in PBS) without primary antibodies, and nonspecific fluorescent staining was not detected under these conditions (Fig. 1, A–D). Images were acquired on a Zeiss LSM 880 Airyscan Elyra S1 confocal microscope (Zeiss) and processed using ImageJ software.

To quantify the volume of NETs present in the lung tissue, six fields (magnification, 20×) were analyzed per patients, Z-stack pictures were acquired, and Imaris software was used, as described previously (Radermecker et al., 2019). Briefly, we performed a three-dimensional reconstruction of structures staining double positive for Cit-H3 (red) and MPO (green), and Imaris provided quantification of the volume of these structures, expressed as cubic micrometer per cubic micrometer of lung tissue. The colocalization analysis method uses three Imaris script/macrotools. The first script processes all the .ims files in a folder. The script thresholds the red Cit-H3 and the green MPO staining. Then, we created a new channel, i.e., the intersection between red threshold and green threshold, where all the voxels have a colocalization equal to 1. Then, the second script measured the volume of the intersection between the red threshold and the green threshold. Finally, the third script measured the total volume of the picture. The script created an Excel .xlsx file containing all the measurements.

To assess for the presence of NETs in entire lung sections, sections were entirely scanned using the Nanozoomer 2.0-HT system equipped with a TRI-CCD camera (0.46 µm/pixel [20×] scanning resolution). Sections were manually screened for the presence of areas rich in structures staining double positive for Cit-H3 and MPO, which were identified as NET-infiltrating areas as marked in Fig. 2 C. The third script measured the total volume of the picture. The script thresholds the red Cit-H3 and the green MPO staining. Then, we created a new channel, i.e., the intersection between red threshold and green threshold, where all the voxels have a colocalization equal to 1. Then, the second script measured the volume of the intersection between the red threshold and the green threshold. Finally, the third script measured the total volume of the picture. The script created an Excel .xlsx file containing all the measurements.

Statistical analyses
Data in Fig. 1 I are presented as mean and individual values and were analyzed for statistical significance using a nonparametric Mann–Whitney U test on mean values, as indicated in the figure legend. P values <0.05 are considered statistically significant.

Online supplemental material
Fig. S1 shows microscopy pictures of immunofluorescence lung sections from non–COVID-19 patients stained with DAPI, anti-MPO, and anti–Cit-H3 antibodies. Fig. S2 shows representative confocal microscopy pictures of immunofluorescence staining from liver, pancreas, kidney, and heart sections from COVID-19 patients stained with DAPI, anti-MPO, and anti–Cit-H3 antibodies. Table S1 contains demographic and clinical characteristics of the non–COVID-19 patients involved in the study.

Acknowledgments
We thank Dr Alexandre Hego from the Grappe Interdisciplinaire de Génoprotéomique Appliquée Flow Cytometry and Cell Imaging Platform; Dr Benoît Misset, Head of the Intensive Care Unit Department; Dr. Alexandra Belayew for helpful discussions; and Pauline Maréchal, Raja Fares, and Ilham Sbai for their excellent technical and administrative support.

C. Oury is Research Director at the National Funds for Scientific Research, Belgium. P. Delvenne is supported by the Leon Fredericq Foundation (Liege, Belgium). T. Marichal is supported by an “Incentive Grant for Scientific Research” of the National Funds for Scientific Research, Belgium (grant no. F.4508.18), by the FRFS-WELBIO (Walloon Excellence in Life Sciences and Biotechnology; grant no. CR-2019s-04R), by the Acteria Foundation, and by an European Research Council Starting Grant (grant no. ERC-StG-2018 IM-ID 801823).

Author contributions: C. Radermecker, C. Oury, P. Delvenne, and T. Marichal conceived the project and were involved in experimental design. C. Radermecker performed most experiments, and analyzed and compiled the data. C. Radermecker and T. Marichal prepared the figures. N. Detrembleur and P. Delvenne performed histopathological analyses of COVID-19 lungs. J. Guiot collected lung samples from COVID-19 patients. E. Cavalier performed clinical biochemistry measurements. M. Henket was involved in the quantification and compilation of hematological parameters. C. d’Emal collected patients’ demographic and clinical characteristics with the help of C. Oury. C. Vanwingerde and D. Cataldo performed scanning of entire immunofluorescence sections. P. Delvenne selected relevant FFPE material. C. Oury, P. Delvenne, and T. Marichal supervised the study and wrote the manuscript. All authors provided feedback on the manuscript.

Disclosures: E. Cavalier reported “other” from Diasorin, Fujirebio, BioMerieux, IDS, Menarini, and Nittobo outside the submitted work. No other disclosures were reported.

Submitted: 2 June 2020
Revised: 10 July 2020
Accepted: 10 August 2020

References
Ackermann, M., S.E. Verleden, M. Kuehnel, A. Haverich, T. Welte, F. Laenger, A. Vanstapel, C. Werlein, H. Stark, A. Tsankov, et al. 2020. Pulmonary Vascular Endotheliitis, Thrombosis, and Angiogenesis in Covid-19. N. Engl. J. Med. 383:120–128. https://doi.org/10.1056/NEJMoa2015432
Ali, R.A., A.A. Gandhi, H. Meng, S. Yalavarthi, A.P. Vreede, S.K. Estes, O.R. Palmer, P.L. Bockenstedt, D.J. Pinsky, J.M. Greve, et al. 2019. Adenosine receptor agonism protects against NETosis and thrombosis in anti-phospholipid syndrome. Nat. Commun. 10:1916. https://doi.org/10.1038/s41467-019-09801-x
Ashar, H.K., N.C. Mueller, J.M. Rudd, T.A. Snider, M. Achanta, M. Prasanthi, S. Pulavendran, P.G. Thomas, A. Ramachandran, J.R. Malayer, et al. 2018. The Role of Extracellular Histones in Influenza Virus Pathogenesis. Am. J. Pathol. 188:135–148. https://doi.org/10.1016/j.ajpath.2017.09.014
Bao, L., W. Deng, B. Huang, H. Gao, J. Liu, L. Ren, Q. Wei, P. Yu, Y. Xu, F. Qi, et al. 2020. The pathogenicity of SARS-CoV-2 in HACE2 transgenic mice. Nature. 583:830–833. https://doi.org/10.1038/s41586-020-2312-y
Barnes, B.J., M.J. Adrover, A. Baxter-Stoltzue, A. Borcuz, J. Coels-Lartigue, J.M. Crawford, J. DuSill-Plenker, P. Guerci, C. Huyhn, J.S. Knight, et al. 2020. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J. Exp. Med. 217: e20200652. https://doi.org/10.1084/jem.20200652
Bendib, I., L. de Chaisemartin, V. Granger, F. Schlemmer, B. Maitre, S. Hüe, M. Surennaud, A. Beldi-Ferchiou, G. Carteux, K. Razzaz, et al. 2019. Neutrophil Extracellular Traps Are Elevated in Patients with Pneumonia.
related Acute Respiratory Distress Syndrome. Anesthesiology. 130:581-591. https://doi.org/10.1097/ALN.0000000000002619
Bikker, J.J., M.V. Mangan, A. Jumaa, J.R. Burton, C. Der Nigoghossian, T. Chuch, S.N. Nouri, I. Desfus, E. Driggan, et al. Global COVID-19 Thrombosis Collaborative Group. 2020. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thromb. Haemost. 120:1004–1024. https://doi.org/10.1055/s-0044-1731552
Boelz, S., P. Amini, H.-J. Anders, F. Andrade, R. Bilyu, S. Chatfield, I. Cichon, D. T. Clancy, J. Desai, T. Dumych, et al. 2019. To NET or not to NET: current opinions and state of the science regarding the formation of neutrophil extracellular traps. Cell Death Differ. 26:395–408. https://doi.org/10.1038/s41418-018-0261-x
Boone, B.A., P. Murthy, J. Miller-Ocuin, W.R. Doerfler, J.T. Ellis, X. Liang, Ramsey, B.J. Rosenstein, A.L. Smith, and M.E. Wohl; The Pulmozyme-1712918 Trials randomised controlled trial. syndrome (ARDS): a structured summary of a study protocol for in patients with SARS-CoV-2-induced acute respiratory distress
F. Lambiotte, S. Le Tacon, M. Cantier, N. Engrand, et al. 2020. Efficacy of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatrics. 146:545–553. https://doi.org/10.1542/peds.2020-21388
Lefrançois, E., B. Mallavia, H. Zhou, C.S. Calfeef, and M.R. Looney. 2018. Maladaptive role of neutrophil extracellular traps in pathogen-induced lung injury. JCI Insight. 3. https://doi.org/10.1172/jci.insight.98178
Li, S., L. Jiang, X. Li, F. Lin, Y. Wang, B. Li, T. Jiang, W. An, S. Liu, H. Liu, et al. 2020. Clinical and pathological investigation of patients with severe COVID-19. JCI Insight. 5. e138070. https://doi.org/10.1172/jci.insight.138070
Mangold, A., S. Alias, T. Scherz, T. Hofbauer, J. Jakowitsch, A. Panzenbóck, D. Simon, D. Laimer, C. Angert, A. Kammerlander, et al. 2015. Coronary neutrophil extracellular trap burden and deoxyribonuclease activity in ST-elevation acute coronary syndrome are predictors of ST-segment resolution and infarct size. Circ. Res. 116:1182–1192. https://doi.org/10.1161/CIRCRESAHA.116.304944
Meher, A.K., M. Spinosa, J.P. Davis, N. Pope, V.E. Laubach, G. Su, V. Serbulea, M. Middleton, E.A., X.-Y. He, F. Denorme, R.A. Campbell, D. Ng, S.P. Salvatore, et al. 2016b. Efficacy of High-Fat Diet on the Formation of Pulmonary Neutrophil Extracellular Traps during in vivo pathogenesis of pneumonia. Arthritis Rheumatol. 853. https://doi.org/10.1002/art.39938
Milatovic, S., A.K. Leitinger, G. Ailawadi, and G.R. Upchurch, Jr.. 2018. Novel Role of IL-1β in Neutrophil Extracellular Trap Formation and Abdominal Aortic Aneurysms. Arterioscler. Thromb. Vasc. Biol. 38:843–853. https://doi.org/10.1161/ATVBAHA.117.309897
Meng, H., S. Yalavarthi, Y. Kanthi, L.F. Mazza, M.A. Elline, C.E. Luke, D.J. Pinsky, P.K. Henke, and J.S. Knight. 2017. In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis. Arthritis Rheumatol. 69:655–667. https://doi.org/10.1002/art.39938
Motta, A.N., K.B. Tan, S. Wang, T. Narasaraju, and V.T.K. Chow. 2016b. Enhanced Neutrophil Extracellular Trap Formation in Acute Respiratory Distress Syndrome. Blood. 20200007008. https://doi.org/10.1182/blood.20200007008
Mikacenic, C., R. Moore, V. Dmyterko, T. West, W.A. Altemeier, W.C. Liles, and C. Loed. 2018. Neutrophil extracellular traps (NETs) are increased in the alveolar spaces of patients with ventilator-associated pneumonia. Crit. Care. 22:358. https://doi.org/10.1186/s13054-018-2290-8
Moorthy, A.N., P. Rai, H. Jiao, S. Wang, K.B. Tan, L. Qin, H. Watanabe, Y. Zhang, N. Teluguakula, and V.T.K. Chow. 2016a. Capsules of virulent Neutrophil Extracellular Traps (NETs) Contribute to Immuno-thrombosis in COVID-19 Acute Respiratory Distress Syndrome. Blood. JCI Insight. 116:1182–1192. https://doi.org/10.1172/jci.insight.98178
Mozzini, C., and D. Girelli. 2020. The role of Neutrophil Extracellular Traps in COVID-19: Only an hypothesis or a potential new field of research? Thromb. Haemost. 121:26–27. https://doi.org/10.1055/a-0380-1940.03011
Murthy, P., A.D. Singh, M.A. Ross, P. Loughran, G.I. Papachristou, D.C. Whitcomb, A.H. Zureikat, M.T. Lotze, H.J. Zeh Lii, et al. 2019. Enhanced Neutrophil Extracellular Trap Formation in Acute Pancreatitis Contributes to Disease Severity and Is Reduced by Chloroquine. Front. Immunol. 10:28. https://doi.org/10.3389/fimmu.2019.00028
Nair, L., K. Martinod, and S.F. De Meyer. 2019. Neutrophil Extracellular Traps in Arterial and Venous Thrombosis. Semin. Thromb. Hemost. 45: 86–93. https://doi.org/10.1055/s-0038-1670040
Moffat, K.I. Pappelbaum, C. Gorzelanny, C. Aponte-Santamarı Caudrillier, A., K. Kessenbrock, B.M. Gilliss, J.X. Nguyen, M.B. Marques, M. Bikdeli, B., M.V. Madhavan, A. Gupta, D. Jimenez, J.R. Burton, C. Der NIchrysanthopoulou, A., I. Mitroulis, E. Apostolidou, S. Arelaki, D. Mikroulis, T. Chen, N., M. Zhou, X. Dong, J. Qu, F. Gong, Y. Han, Y. Qiu, J. Wang, Y. Liu, Y. Wei, et al. 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 395:507-513. https://doi.org/10.1016/S0140-6736(20)30021-7
Chrysanthopoulou, A., I. Mitroulis, E. Apostolidou, S. Arelaki, D. Mikroulis, T. Konstantinidis, E. Sivridis, M. Koffa, A. Giatromanolaki, D.T. Boumpas, et al. 2014. Neutrophil extracellular traps promote differentiation and function of fibroblasts. J. Pathol. 239:294–307. https://doi.org/10.1002/path.4389
Connors, J.M., and J.H. Levy. 2020. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 135:2033–2040. https://doi.org/10.1182/blood.2020006000
Desilles, J.P., C. Gregoire, C. Le Cossec, J. Lambert, O. Mophahe, M.R. Lossér, F. Lambiotte, S. Le Tacon, M. Cantier, N. Engrand, et al. 2020. Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial. Trials. 21:548. https://doi.org/10.1186/s13063-020-04488-8
Fuchs, H.J., D.S. Borowitz, D.H. Christiansen, E.M. Morris, M.L. Nash, B.W. Burton, C. Der Ni-
Figure S1. **No evidence of NETs in postmortem lung biopsy specimens from non–COVID-19 patients.** (A) Photographs of entire antibody-stained immunofluorescence lung sections from non–COVID-19 patients. (B) Magnification of NET-rich zones, indicated by white boxes in A. (C) Representative confocal microscopy pictures of immunofluorescence staining of lung sections from non–COVID-19 patients (MPO [red] and Cit-H3 [red] merged with DAPI [blue]). Scale bars, 1 mm (A); 100 µm (B); 20 µm (C).
Table S1 is provided online as a separate Word file and contains demographic and clinical characteristics of the non–COVID-19 patients involved in the study.

Figure S2. **No evidence of NETs in postmortem biopsy specimens from other organs in COVID-19 patients.** (A–D) Representative confocal microscopy pictures of immunofluorescence staining from (A) liver, (B) pancreas, (C) kidney, and (D) heart sections from two COVID-19 patients are shown (MPO [red] and Cit-H3 [red] merged with DAPI [blue]). Areas containing MPO+ neutrophils are shown. Scale bars, 20 µm.